---
pmid: '14704432'
title: In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.
authors:
- Vassilev LT
- Vu BT
- Graves B
- Carvajal D
- Podlaski F
- Filipovic Z
- Kong N
- Kammlott U
- Lukacs C
- Klein C
- Fotouhi N
- Liu EA
journal: Science
year: '2004'
full_text_available: false
doi: 10.1126/science.1092472
---

# In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.
**Authors:** Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA
**Journal:** Science (2004)
**DOI:** [10.1126/science.1092472](https://doi.org/10.1126/science.1092472)

## Abstract

1. Science. 2004 Feb 6;303(5659):844-8. doi: 10.1126/science.1092472. Epub 2004
Jan  2.

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.

Vassilev LT(1), Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, 
Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA.

Author information:
(1)Department of Discovery Oncology, Roche Research Center, Hoffmann-La Roche, 
Inc., Nutley, NJ 07110, USA. lyubomir.vassilev@roche.com

MDM2 binds the p53 tumor suppressor protein with high affinity and negatively 
modulates its transcriptional activity and stability. Overexpression of MDM2, 
found in many human tumors, effectively impairs p53 function. Inhibition of 
MDM2-p53 interaction can stabilize p53 and may offer a novel strategy for cancer 
therapy. Here, we identify potent and selective small-molecule antagonists of 
MDM2 and confirm their mode of action through the crystal structures of 
complexes. These compounds bind MDM2 in the p53-binding pocket and activate the 
p53 pathway in cancer cells, leading to cell cycle arrest, apoptosis, and growth 
inhibition of human tumor xenografts in nude mice.

DOI: 10.1126/science.1092472
PMID: 14704432 [Indexed for MEDLINE]
